1-2 of 2
Kevin Chau
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody–Drug Conjugate for Treatment of CLDN18.2-Positive Cancers

Neil A. O'Brien, Martina S.J. McDermott, Jun Zhang, Ke Wei Gong, Ming Lu, Benjamin Hoffstrom, Tong Luo, Raul Ayala, Kevin Chau, Min Liang, Athena M. Madrid, Timothy R. Donahue, John A. Glaspy, Leonard Presta, Dennis J. Slamon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12): 1365–1375.
https://doi.org/10.1158/1535-7163.MCT-23-0353
Published: 01 December 2023
View article titled, Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody–Drug Conjugate for Treatment of CLDN18.2-Positive Cancers
Open the PDF for Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody–Drug Conjugate for Treatment of CLDN18.2-Positive Cancers in another window
Includes: Supplementary data
Journal Articles

Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer

Neil O'Brien, Dylan Conklin, Richard Beckmann, Tong Luo, Kevin Chau, Josh Thomas, Ann Mc Nulty, Christophe Marchal, Ondrej Kalous, Erika von Euw, Sara Hurvitz, Colleen Mockbee, Dennis J. Slamon
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (5): 897–907.
https://doi.org/10.1158/1535-7163.MCT-17-0290
Published: 30 April 2018
View article titled, Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer
Open the PDF for Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer in another window
Includes: Supplementary data